TargetBeta
CD38
CD38 molecule · also cADPR1 · CD molecules
11 programs in company-led studies act on CD38, from 10 companies: 6 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (9 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| daratumumabrule | Johnson & Johnson | phase 4 | 4410 running | – | NCIt |
| lumrotatugrule | Keymed Biosciences | phase 3 | 108 running | – | NCIt |
| felzartamabrule | Biogen | phase 3 | 157 running | – | NCIt |
| isatuximabrule | Sanofi | phase 3 | 236 running | – | NCIt |
| Anti-CD38 Monoclonal Antibody SCTC21Crule | Sinocelltech Group | phase 3 | 55 running | – | NCIt |
| mezagitamabrule | Takeda | phase 3 | 114 running | – | NCIt |
| sanritatugrule | Hangzhou Sumgen Biotech | phase 3 | 54 running | – | NCIt |
| CID-103rule | CASI Pharmaceuticals | phase 2 | 32 running | – | NCIt |
| Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001 | AbbVie | phase 2 | 22 running | CD3E, TNFRSF17 | the company's pipeline |
| Anti-CD38 Monoclonal Antibodyrule | Chongqing Genrix Biopharmaceutical | phase 2 | 11 running | – | NCIt |
| Anti-CD38 Antibody-drug Conjugate ABBV-438 | AbbVie | phase 1 | 11 running | – | the company's pipeline |
Also acted on by the same programs
Conditions their studies are in
- Multiple Myeloma, 11 programs
- Lupus Erythematosus, Systemic, 4 programs
- Glomerulonephritis, IGA, 3 programs
- Amyloidosis, 2 programs
- Precursor Cell Lymphoblastic Leukemia-Lymphoma, 2 programs
- Purpura, Thrombocytopenic, Idiopathic, 2 programs
- Anemia, Aplastic, 1 program
- Anemia, Hemolytic, Autoimmune, 1 program
- Glomerulonephritis, 1 program
- Glomerulonephritis, Membranous, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 1, 2026felzartamab · Biogen · phase 3 · NCT06685757
- Mar 2027lumrotatug · Keymed Biosciences · phase 3 · NCT06830395
- Mar 8, 2027daratumumab · Johnson & Johnson · phase 4 · NCT06952478
- Mar 31, 2027sanritatug · Hangzhou Sumgen Biotech · phase 3 · NCT07764627
- Apr 2027Anti-CD38 Monoclonal Antibody SCTC21C · Sinocelltech Group · phase 3 · NCT07538154
- Apr 5, 2027isatuximab · Sanofi · phase 3 · NCT03319667
- Jul 2027Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001 · AbbVie · phase 2 · NCT05862012
- Mar 16, 2028mezagitamab · Takeda · phase 3 · NCT06722235
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.